Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Three­'s com­pa­ny: Sanofi fol­lows lead of Lil­ly and No­vo, slash­es in­sulin price by 78% and caps out-of-pock­et costs

Sanofi to­day joined with the oth­er two in­sulin jug­ger­nauts in the US to low­er the price of its best-sell­ing in­sulin prod­uct, Lan­tus (in­sulin glargine), by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.